US-based biotech firm Zymergen on Thursday announced that it raised $400 million in a Series C funding round led by SoftBank Vision Fund. Goldman Sachs and Hanwha Asset Management, as well as existing investors including True Ventures, participated in the round. Founded in 2013, Zymergen integrates machine learning with genomics for use in pharmaceutical, chemical and agriculture industries.

This short was originally published on Inshorts, based on an article in TechCrunch.